Loading...
Loading...
ARVN| Name | Value |
|---|---|
| Revenues | 34.6M |
| Cost of Revenue | 1.7M |
| Gross Profit | 32.9M |
| Operating Expense | 108.5M |
| Operating I/L | -73.9M |
| Other Income/Expense | 10.0M |
| Interest Income | 10.0M |
| Pretax | -63.9M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -64.0M |
Arvinas, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of therapies that target disease-causing proteins for degradation. Its lead product candidates include Bavdegalutamide, ARV-471, and ARV-766, which are proteolysis targeting chimera (PROTAC) protein degraders designed to treat metastatic castration-resistant prostate cancer and metastatic ER positive/HER2 negative breast cancer. The company generates revenue through collaborations with industry leaders such as Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG, leveraging its innovative protein degradation technology to develop potential treatments for various diseases.
